+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Monoclonal Antibody Therapeutics Market by Source (Chimeric, Human, Humanized), End User (Hospitals, Private Clinics, Research Institute), Application - Forecast 2024-2030

  • PDF Icon

    Report

  • 188 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 4829819
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Monoclonal Antibody Therapeutics Market size was estimated at USD 158.91 billion in 2023, USD 178.77 billion in 2024, and is expected to grow at a CAGR of 12.59% to reach USD 364.53 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Monoclonal Antibody Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Monoclonal Antibody Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Monoclonal Antibody Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Envigo, F. Hoffmann-La Roche Ltd, GenScript, GlaxoSmithKline Plc, Johnson & Johnson, Merck Sharp & Dohme Corp.,, Novartis International AG, Pfizer Inc, and Sanofi S.A.

Market Segmentation & Coverage

This research report categorizes the Monoclonal Antibody Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Source
    • Chimeric
    • Human
    • Humanized
  • End User
    • Hospitals
    • Private Clinics
    • Research Institute
  • Application
    • Autoimmune Diseases
    • Cancer
    • Hematological Diseases
    • Infectious Diseases
    • Ophthalmological Diseases
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Monoclonal Antibody Therapeutics Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Monoclonal Antibody Therapeutics Market?
  3. What are the technology trends and regulatory frameworks in the Monoclonal Antibody Therapeutics Market?
  4. What is the market share of the leading vendors in the Monoclonal Antibody Therapeutics Market?
  5. Which modes and strategic moves are suitable for entering the Monoclonal Antibody Therapeutics Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Monoclonal Antibody Therapeutics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing adoption of monoclonal antibody therapeutics in cancer treatments
5.1.1.2. Increasing approvals of monoclonal antibodies
5.1.1.3. Rising use of monoclonal antibodies for the treatment of autoimmune diseases
5.1.2. Restraints
5.1.2.1. High cost of clinical research and development
5.1.3. Opportunities
5.1.3.1. Increasing product launches and investment in R&D
5.1.3.2. Increasing regulatory support for the treatment of rare diseases
5.1.4. Challenges
5.1.4.1. Variation in results from patient to patient
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Monoclonal Antibody Therapeutics Market, by Source
6.1. Introduction
6.2. Chimeric
6.3. Human
6.4. Humanized
7. Monoclonal Antibody Therapeutics Market, by End User
7.1. Introduction
7.2. Hospitals
7.3. Private Clinics
7.4. Research Institute
8. Monoclonal Antibody Therapeutics Market, by Application
8.1. Introduction
8.2. Autoimmune Diseases
8.3. Cancer
8.4. Hematological Diseases
8.5. Infectious Diseases
8.6. Ophthalmological Diseases
9. Americas Monoclonal Antibody Therapeutics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Monoclonal Antibody Therapeutics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Monoclonal Antibody Therapeutics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AbbVie Inc.
13.1.2. Amgen Inc.
13.1.3. Bayer AG
13.1.4. Biogen Inc.
13.1.5. Bristol-Myers Squibb Company
13.1.6. Eli Lilly and Company
13.1.7. Envigo
13.1.8. F. Hoffmann-La Roche Ltd
13.1.9. GenScript
13.1.10. GlaxoSmithKline Plc
13.1.11. Johnson & Johnson
13.1.12. Merck Sharp & Dohme Corp.,
13.1.13. Novartis International AG
13.1.14. Pfizer Inc
13.1.15. Sanofi S.A
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. MONOCLONAL ANTIBODY THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. MONOCLONAL ANTIBODY THERAPEUTICS MARKET DYNAMICS
FIGURE 7. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
FIGURE 8. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 10. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 12. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. MONOCLONAL ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 6. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 10. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 14. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 29. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 30. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 31. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 32. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 33. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 34. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 42. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 44. AUSTRALIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. AUSTRALIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 46. CHINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 47. CHINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. CHINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 49. INDIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 50. INDIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. INDIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 53. INDONESIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. INDONESIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. JAPAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 56. JAPAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. JAPAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 59. MALAYSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. MALAYSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 62. PHILIPPINES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. PHILIPPINES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 65. SINGAPORE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. SINGAPORE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 68. SOUTH KOREA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. SOUTH KOREA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 71. TAIWAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. TAIWAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. THAILAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 74. THAILAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. THAILAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 77. VIETNAM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. VIETNAM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 83. DENMARK MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 84. DENMARK MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. DENMARK MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 86. EGYPT MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 87. EGYPT MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. EGYPT MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. FINLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 90. FINLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. FINLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. FRANCE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 93. FRANCE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. FRANCE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. GERMANY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 96. GERMANY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. GERMANY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 99. ISRAEL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. ISRAEL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 101. ITALY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 102. ITALY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. ITALY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 105. NETHERLANDS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. NETHERLANDS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 110. NORWAY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 111. NORWAY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. NORWAY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 113. POLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 114. POLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. POLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 116. QATAR MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 117. QATAR MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. QATAR MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 128. SPAIN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 129. SPAIN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. SPAIN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. SWEDEN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 137. TURKEY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 138. TURKEY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. TURKEY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 146. MONOCLONAL ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 147. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 148. MONOCLONAL ANTIBODY THERAPEUTICS MARKET LICENSE & PRICING

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Envigo
  • F. Hoffmann-La Roche Ltd
  • GenScript
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck Sharp & Dohme Corp.,
  • Novartis International AG
  • Pfizer Inc
  • Sanofi S.A

Methodology

Loading
LOADING...

Table Information